Famotidine disposition in children and adolescents with chronic renal insufficiency

Journal of Clinical Pharmacology

Volumn 43, Issue 1, 2003, Pages 7-14

  Maples, Holly D ^a   James, Laura P ^a,f   Stowe, Cindy D ^a   Jones, Deborah P ^b   Hak, Emily B ^b   Blumer, Jeffrey L ^c   Vogt, Beth ^c   Wilson, John T ^d   Kearns, Gregory L ^e   Wells, Thomas G ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FAMOTIDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; PLASMA CLEARANCE; SCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FAMOTIDINE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; TISSUE DISTRIBUTION;

EID: 0037215305     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270002239700     Document Type: Article

References (22)

1. James LP, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet 1996;31:103-110.
2. Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U: Famotidine: Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. Clin Pharmacokinet 1990;18:77-81.
3. Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey GA II: Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988;34:41-46.
4. Yeh KC, Chremos AN, Lin JH, Constanzer ML, Kanovsky SM, Hucker HB, et al: Single-dose pharmacokinetics and bioavailability of famotidine in man: Results of multicenter collaborative studies. Biopharm Drug Dispos 1987;8:549-560.
5. Takabatake T, Ohta H, Maekawa M, Yamamoto Y, Ishida Y, Hara H, et al: Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 1985;28:327-331.
6. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR: Disposition of famotidine in renal insufficiency. J Clin Pharmacol 1987;27:782-787.
7. James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL: Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 1998;38:1089-1095.
8. Murphy MG, James LP, Wenning L, Blumer JL, Panebianco D, Yeh K, Kearns GL: Famotidine pharmacokinetics in infants. Clin Pharm Ther 2001;69(2):P81.
9. Gladziwa U, Klotz U, Krishna DR, Schmitt H, Glockner WM, Mann H: Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol 1988;26:315-321.
10. Ventkateswaran PS, Jeffers A, Hocken AG: Gastric acid secretion in chronic renal failure. Br Med J 1972;4:22-23.
11. Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Filingeri V, Cesca D, et al: Assessment of the upper gastrointestinal tract in hemodialysis patients awaiting renal transplantation. Am J Gastroenterol 1983;78:328-331.
12. Shepherd AM, Stewart WK, Wormsley KG: Peptic ulceration in chronic renal failure. Lancet 1973;1:1357-1359.
13. Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Cesca D, Boffo V, et al: The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int Suppl 1985;17:S157-S160.
14. Yoshimoto K, Saima S, Echizen H, Nakamura Y, Kondo T, Yagishita Y, et al: Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther 1994;55:693-700.
15. Schwartz GJ, Brion LP, Spitzer A: The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987;34:571-590.
16. Wagner JG: Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 1976;4:443-467.
17. Landaw EM, DiStefano JJ III: Multiexponential, multicompartmental, and noncompartmental modeling: II. Data analysis and statistical considerations. Am J Physiol 1984;246:R665-R677.
18. Merck & Co., Inc. Package Literature for Pepcid® [Famotidine). March 2001.
19. Kearns GL, Reed MD: Clinical pharmacokinetics in infants and children: A reappraisal. Clin Pharmacokinet 1989;17:29-67.
20. Nagita A, Manago M, Aoki S, Mino M, Suzuki K, Ashida K: Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 1994;16:444-449.
21. Dowling TC, Frye RF, Fraley DS, Matzke GR: Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine. Kidney Int 2001;59:295-303.
22. Maish WA, McCubbin MM, Letzig LG, Farrar HC III, Kearns GL: Pharmacokinetics of famotidine in patients with cystic fibrosis. J Clin Pharmacol 1998;38:1010-1016.